Andreas Schreiner, MD Dr Andreas Schreiner is a certified psychiatrist and
neurologist who currently holds the position of Vice
President Medical & Scientific Affairs CNS and Internal
Medicine at Janssen-Cilag Europe, Middle East and
Dr Schreiner studied medicine at the Universities of
Heidelberg and Mannheim, Germany, and completed residencies in the Department of
Neurology at the University Hospital in Mannheim and in Psychiatry at the Central
Institute of Mental Health Mannheim, University of Heidelberg. He joined Janssen-Cilag
Medical & Scientific Affairs in 1999.
Dr Schreiner is frequently lecturing and has given more than 500 scientific presentations
at national and international meetings. He has also published more than 50 peer-
reviewed manuscripts in national and international journals, has written several book
chapters and has presented more than 300 abstracts at national and international
meetings. Dr Schreiner is a member of many scientific associations including the
Schizophrenia International Research Society (SIRS), the German Society of Psychiatry,
Psychotherapy and Neurology (DGPPN) the American Academy of Neurology (AAN)
and the American Epilepsy Society (AES).
Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in
schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment. European Psychiatry (2009), doi:10.1016/j.eurpsych2009.09.001
Kluger G, Schauble B, Rettig K, Schreiner A, Holthausen H. Effectiveness of low dose of topiramate following
rapid titration in multiply handicapped children and difficult-to-treat epilepsy. Neuropediatrics 2009; 40: 61-65
Schreiner A, Stollhoff K, Ossig W, Unkelbach S, Luer W, Bogdanow M, Schauble B. Conversion from valproic
acid onto topiramate in adolescents and adults with epilepsy. Acta Neurol.Scand. 2009; 119: 304-312
Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM. Paliperidone extended-release
tablets in schizophrenia patients previously treated with risperidone. Int.Clin.Psychopharmacol. 2008; 23: 209-215
Stefan H, Hubbertz L, Peglau I, Berrouschot J, Kasper B, Schreiner A, Krimmer J, Schauble B. Epilepsy
outcomes in elderly treated with topiramate. Acta Neurol.Scand. 2008; 118: 164-174
Forsthoff A, Grunze H, Seemuller F, Stampfer R, Dittmann S, Amann B, Schmidt F, Schafer M, Hermle L,
Walden J, Schreiner A. Risperidone monotherapy in manic inpatients: an open label, multicentre trial. World J.Biol.Psychiatry 2007; 8: 256-261
Korinthenberg R, Schreiner A. Topiramate in children with west syndrome: a retrospective multicenter
evaluation of 100 patients. J.Child Neurol. 2007; 22: 302-306
Naber D, Greenspan A, Schreiner A. Efficacy and safety of risperidone in the treatment of elderly patients
suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Psychopharmacology (Berl) 2007; 191: 1027-1029
Raedler TJ, Schreiner A, Naber D, Wiedemann K. Early onset of treatment effects with oral risperidone.
10. Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. Initial treatment of severe acute psychosis with fast
orally disintegrating risperidone tablets. Pharmacopsychiatry 2006; 39: 209-212
11. Raedler TJ, Schreiner A, Naber D, Wiedemann K. Gender-specific effects in the treatment of acute
schizophrenia with risperidone. Pharmacopsychiatry 2006; 39: 171-174
12. Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, Schreiner A, Remschmidt H.
[Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]. Z.Kinder Jugendpsychiatr.Psychother. 2006; 34: 257-265
13. Glick ID, Shkedy Z, Schreiner A. Differential early onset of therapeutic response with risperidone vs
conventional antipsychotics in patients with chronic schizophrenia. Int.Clin.Psychopharmacol. 2006; 21: 261-266
14. Schreiner A. Treatment of bipolar mania with risperidone. Psychiatr.Prax. 2006; 33 Suppl 1: S12-S17
15. Hewer W, Schreiner A. Psychiatrische Notfälle [Emergencies in Psychiatry] Kursbuch Notfallmedizin.
16. Stoppe G, Schreiner A, Schmitt AB. Changeover to risperidone after treatment with conventional low potency
neuroleptics in dementia patients. An observation study during usage. Dtsch Med Wochensch. 206; Mar 3; 131 (9): 423-9
17. Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Braunig P, Medori R. Long-acting
risperidone in stable patients with schizoaffective disorder. J.Psychopharmacol. 2005; 19: 22-31
18. Groselj J, Guerrini R, van OJ, Lahaye M, Schreiner A, Schwalen S. Experience with topiramate monotherapy
in elderly patients with recent-onset epilepsy. Acta Neurol.Scand. 2005; 112: 144-150
19. Haffmanns PMJ, Oolders HJ, Hoencamp E, Schreiner A. Sleep quality in schizophrenia and the effects of
atypical antipsychotic medication. Acta Neuropsychiatrica 2005; 16(6):281-289
20. Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Ruther E. Risperidone: an open-label, observational
study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. J.Clin.Psychopharmacol. 2005; 25: 293-300
21. Lejeune J, Larmo I, Chrzanowski W, Witte R, Karavatos A, Schreiner A, Lex A, Medori R. Oral risperidone plus
oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int.Clin.Psychopharmacol. 2004; 19: 259-269
22. Raedler TJ, Schreiner A, Naber D, Wiedemann K. Risperidone in the treatment of acute schizophrenia.
J.Clin.Psychopharmacol. 2004; 24: 335-338
23. Schreiner A, Pohlmann-Eden B. Value of the early electroencephalogram after a first unprovoked seizure.
Clin.Electroencephalogr. 2003; 34: 140-144
24. Jatzko A, Ries S, Schreiner A, Braus DF. [Acute tongue and pharyngeal spasms during changeover from
clozapine to amisulpride. A case example]. Nervenarzt 2000; 71: 919-922
25. Schreiner A, Waldherr R, Rohmeiss P, Hewer W. Focal segmental glomerulosclerosis and lithium treatment.
26. Schreiner A, Hewer W. Is clozapine useful in schizophrenic patients with concomitant chronic inflammatory
disease? Pharmacopsychiatry (2000); 33:153-4
27. Schreiner A, Pohlmann-Eden B. Cerebral hypoxia after cardiopulmonary resuscitation. Lancet 1999; 353: 750-
28. Pohlmann-Eden B, Schreiner A. Epileptology of the first-seizure presentation. Lancet 1998; 352: 1855-1856
29. Fassbender K, Schmidt R, Schreiner A, Fatar M, Muhlhauser F, Daffertshofer M, Hennerici M. Leakage of
brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J.Neurol.Sci. 1997; 148: 101-105
30. Schreiner A, Pohlmann-Eden B, Schwartz A, Hennerici M. Epileptic seizures in subcortical vascular
encephalopathy. J.Neurol.Sci. 1995; 130: 171-177
31. Rother J, Schreiner A, Wentz KU, Hennerici M. Hypoglycemia presenting as basilar artery thrombosis. Stroke
GROUPS RECOMMENDED TO RECEIVE FLU VACCINE Flu vaccine should be offered to the eligible groups set out in the table below (Annex A, page 9 in the annual flu letter): Eligible groups Further detail All patients aged "Sixty-five and over" is defined as those aged 65 years and over on 31 March 2014 65 years and over (i.e. born on or before 31 March 1949). Asthma
Andreas Schreiner, MD